AnteoTech (ADO) Q2 2026 TU earnings summary

Executive summary

• Focused on expanding product sales pipeline and accelerating growth via new joint development partnerships in both advanced battery and life sciences sectors.

• Achieved significant technical milestones in battery technology and secured new orders and evaluations in life sciences.

• Completed a $3.5 million capital raise post-quarter, strengthening financial runway for 2026.

Financial highlights

• Closing cash of A$1.4 million as of 31 December 2025, with no debt.

• Pro-forma cash balance of A$4.9 million post-capital raise, expected to fund operations through CY2026.

• Net cash outflows from operating activities were A$1.57 million for the quarter.

• Customer receipts totaled A$85,000 for the quarter; additional A$275,000 received in January 2026.

Outlook and guidance

• Aims to convert ongoing customer trials in both Life Sciences and Advanced Battery Technologies into sales, especially in CLIA, ELISA, and Anteo S products.

• Plans to attend major industry conferences and expand sales efforts in India and the US.

• Anticipates further sales to Serum Institute of India and new product launches in 2026.